首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum.
【24h】

The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum.

机译:从人血清中进行免疫亲和纯化后,通过高效液相色谱和荧光检测对单克隆抗体曲妥珠单抗进行生物分析。

获取原文
获取原文并翻译 | 示例
           

摘要

For the quantification of therapeutic monoclonal antibodies in biological specimens, enzyme-linked immunosorbent assay (ELISA) is the most widely used technique. ELISA's have some limitations and therefore alternative analytical techniques are being explored. In this study we describe the development of a bioanalytical assay using high-performance liquid chromatography (HPLC) coupled with fluorescence detection for the bioanalysis of the monoclonal antibody trastuzumab. Different extraction procedures were explored, like isolation using protein A and protein G. Finally a method using immuno-affinity purification has been developed. Trastuzumab is isolated from human serum using sepharose coupled with anti-trastuzumab idiotype antibodies. After extraction samples are injected onto a Zorbax 300SB C8 column at 75 degrees C using the organic solvents isopropanol and acetonitrile with high eluotropic strengths. The assay quantifies trastuzumab from 5 to 40 microg/mL in human serum with accuracies <20%. Samples with concentrations above the upper limit of quantification (>ULOQ; >40 microg/mL) can be diluted 5 times with control human serum prior to sample pre-treatment. The assay can now be used to analyse serum samples of patients treated with trastuzumab. The obtained results are comparable to those obtained using ELISA. This is the first report describing a bioanalytical assay using HPLC and fluorescence detection for the quantification of a monoclonal antibody at the intact protein level in human serum. This unique approach has the advantage compared to ELISA that a HPLC separation step is introduced to improve the selectivity. This method is a potential alternative to ELISA to support pharmacokinetic evaluations. However, for purification of trastuzumab from serum anti-idiotype antibodies are necessary. These anti-idiotype antibodies are also used in ELISA and as ELISA is more sensitive and less labor-intensive, ELISA probably remains the analytical technique of first choice.
机译:为了量化生物学标本中的治疗性单克隆抗体,酶联免疫吸附测定(ELISA)是最广泛使用的技术。 ELISA具有某些局限性,因此正在探索其他分析技术。在这项研究中,我们描述了使用高效液相色谱(HPLC)结合荧光检测对单克隆抗体曲妥珠单抗进行生物分析的生物分析方法的发展。探索了不同的提取程序,例如使用蛋白A和蛋白G进行分离。最后,开发了一种使用免疫亲和纯化的方法。使用琼脂糖与抗曲妥珠单抗独特型抗体从人血清中分离曲妥珠单抗。萃取后,使用有机溶剂异丙醇和乙腈,以高电溶强度在75摄氏度下将样品注入Zorbax 300SB C8色谱柱。该测定法可将曲妥珠单抗定量在人血清中从5到40微克/毫升,准确度<20%。浓度高于定量上限(> ULOQ;> 40 microg / mL)的样品可以在样品预处理之前用对照人血清稀释5倍。该测定法现在可用于分析曲妥珠单抗治疗的患者的血清样品。所得结果与使用ELISA获得的结果相当。这是第一份描述使用HPLC和荧光检测对人血清中完整蛋白水平的单克隆抗体进行定量的生物分析测定的报告。与ELISA相比,这种独特的方法的优势在于引入了HPLC分离步骤以提高选择性。此方法是ELISA的潜在替代方法,可支持药代动力学评估。但是,从血清中提取曲妥珠单抗必须是抗独特型抗体。这些抗独特型抗体也用于ELISA中,因为ELISA灵敏度更高,劳动强度较小,所以ELISA可能仍然是首选的分析技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号